NOTICE: The Drug Law Center is no longer accepting these type of cases. This page is strictly for informational purposes. We appreciate your cooperation and understanding by not contacting our office on these cases. We are actively investigating and prosecuting cases involving Valsartan cancers. For information on Valsartan lawsuits, look here.
Ever since the voluntary Stryker hip recall initiated in 2012, thousands of patients have been negatively impacted. These patients have suffered from revision hip surgeries, development of pseudotumors, extensive pain, swelling, metallosis, and even nerve damage. The Stryker Rejuvenate and ABG II systems were recalled after numerous medical research studies indicated that they were prone to corrosion and fretting. Metal-on-metal hip implants, such as the ones produced by Stryker, have a tendency to wear over time. As the hip implant becomes worn, it releases metal ions into the bloodstream.
Until now, the media has rarely addressed the impact of the Stryker hip recall litigation efforts on the actual profitability of the business. For the first time, the Wall Street Journal (WSJ) recently reported that Stryker suffered a tremendous 77 percent drop in profits for the first quarter of 2014 (for additional information about the corporate history look here). From this figure, one can predict that investors will likely continue to lose faith in Stryker Orthopaedics. Investing in Stryker is becoming unattractive as the company has now developed a reputation for producing defective and high-risk hip implants.